Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

    Results: 9

    1.

    Docetaxel-induced skin toxicities in breast cancer patients subsequent to paclitaxel shortage: a case series and literature review.

    Poi MJ, Berger M, Lustberg M, Layman R, Shapiro CL, Ramaswamy B, Mrozek E, Olson E, Wesolowski R.

    Support Care Cancer. 2013 May 19. [Epub ahead of print]

    PMID:
    23686402
    [PubMed - as supplied by publisher]
    2.

    Human Vγ2Vδ2 T cells limit breast cancer growth by modulating cell survival-, apoptosis-related molecules, and microenvironment in tumors.

    Aggarwal R, Lu J, Kanji S, Das M, Joseph M, Lustberg MB, Ray A, Pompili VJ, Shapiro CL, Das H.

    Int J Cancer. 2013 Apr 18. doi: 10.1002/ijc.28217. [Epub ahead of print]

    PMID:
    23595559
    [PubMed - as supplied by publisher]
    3.

    Severe and prolonged lymphopenia observed in patients treated with bendamustine and erlotinib for metastatic triple negative breast cancer.

    Layman RM, Ruppert AS, Lynn M, Mrozek E, Ramaswamy B, Lustberg MB, Wesolowski R, Ottman S, Carothers S, Bingman A, Reinbolt R, Kraut EH, Shapiro CL.

    Cancer Chemother Pharmacol. 2013 May;71(5):1183-90. doi: 10.1007/s00280-013-2112-2. Epub 2013 Feb 21.

    PMID:
    23430121
    [PubMed - in process]
    4.

    Bone health in adult cancer survivorship.

    Lustberg MB, Reinbolt RE, Shapiro CL.

    J Clin Oncol. 2012 Oct 20;30(30):3665-74. doi: 10.1200/JCO.2012.42.2097. Epub 2012 Sep 24. Review.

    PMID:
    23008309
    [PubMed - indexed for MEDLINE]
    5.

    Microcirculatory fraction (MCF(I)) as a potential imaging marker for tumor heterogeneity in breast cancer.

    Yang X, Mrozek E, Lustberg M, Jia G, Sammet S, Sammet C, Shapiro C, Knopp MV.

    Magn Reson Imaging. 2012 Oct;30(8):1059-67. doi: 10.1016/j.mri.2012.04.026. Epub 2012 Aug 11.

    PMID:
    22884756
    [PubMed - indexed for MEDLINE]
    6.

    Phase I/II trial of non-cytotoxic suramin in combination with weekly paclitaxel in metastatic breast cancer treated with prior taxanes.

    Lustberg MB, Pant S, Ruppert AS, Shen T, Wei Y, Chen L, Brenner L, Shiels D, Jensen RR, Berger M, Mrozek E, Ramaswamy B, Grever M, Au JL, Wientjes MG, Shapiro CL.

    Cancer Chemother Pharmacol. 2012 Jul;70(1):49-56. doi: 10.1007/s00280-012-1887-x. Epub 2012 May 22.

    PMID:
    22729159
    [PubMed - indexed for MEDLINE]
    7.

    Pneumocystis jiroveci Pneumonia in an Atypical Host.

    Reinbolt RE, Alam S, Layman R, Shapiro C, Lustberg M.

    Clin Breast Cancer. 2012 Apr;12(2):138-41. doi: 10.1016/j.clbc.2011.10.003. Epub 2011 Dec 1. No abstract available.

    PMID:
    22133356
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    8.

    Feasibility of stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction.

    Berger MJ, Dunlea LJ, Rettig AE, Lustberg MB, Phillips GS, Shapiro CL.

    Support Care Cancer. 2012 Sep;20(9):1991-7. doi: 10.1007/s00520-011-1303-9. Epub 2011 Nov 17.

    PMID:
    22089428
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    9.

    Phase II trial of neoadjuvant exemestane in combination with celecoxib in postmenopausal women who have breast cancer.

    Lustberg MB, Povoski SP, Zhao W, Ziegler RM, Sugimoto Y, Ruppert AS, Lehman AM, Shiels DR, Mrozek E, Ramaswamy B, Layman RM, Brueggemeier RW, Shapiro CL.

    Clin Breast Cancer. 2011 Aug;11(4):221-7. doi: 10.1016/j.clbc.2011.03.022. Epub 2011 May 19.

    PMID:
    21729671
    [PubMed - indexed for MEDLINE]
    Free PMC Article

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Search details

      See more...

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk